Equity Overview
Price & Market Data
Price: $2.90
Daily Change: -$0.15 / 5.17%
Range: $2.84 - $3.19
Market Cap: $254,908,992
Volume: 806,225
Performance Metrics
1 Week: 21.67%
1 Month: -5.81%
3 Months: -35.11%
6 Months: -61.07%
1 Year: -37.74%
YTD: -47.29%
Company Details
Employees: 59
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.